There are currently 28 active clinical trials seeking participants for Cirrhosis research studies. The states with the highest number of trials for Autism participants are California, Virginia, Texas and New York.
Liver Cirrhosis Network Cohort Study
NCT05740358
Recruiting
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: University of California San Diego NAFLD Research Center, La Jolla, California +13 locations
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis
Register for Updates
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
NCT06052176
Recruiting
Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial changes. This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over 8 weeks with biological sampling and cognitive and health related quality of life (HRQOL) testing with... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/27/2023
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, Virginia
Conditions: Cirrhosis, Hepatic Encephalopathy
Register for Updates
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
NCT05548452
Recruiting
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, Virginia +1 locations
Conditions: Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
Register for Updates
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
NCT05998330
Recruiting
The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specialty focused on lessening (or "palliating") symptoms and assisting in coping with serious illness.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver, Advanced Cirrhosis
Register for Updates
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
NCT05486572
Recruiting
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mor... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/29/2023
Locations: VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington
Conditions: Carcinoma, Hepatocellular, Cirrhosis
Register for Updates
Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia
NCT03059030
Recruiting
Evaluate the safety and efficacy of Yttrium-90 (90Y) radioembolization for the management of thrombocytopenia.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
11/08/2023
Locations: Northwestern University/Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Thrombocytopenia, Cirrhosis
Register for Updates
Adverse Outcomes and Mortality in Liver Transplant
NCT05477277
Recruiting
Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Mayo Clinic Arizona, Phoenix, Arizona
Conditions: End Stage Liver DIsease, Sarcopenia, Sarcopenic Obesity, Cirrhosis
Register for Updates
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
NCT05045482
Recruiting
A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
10/06/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
Register for Updates
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
NCT06007846
Recruiting
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: Inova Schar Cancer Institute, Fairfax, Virginia +1 locations
Conditions: Hepatocellular Carcinoma, Cirrhosis
Register for Updates
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT05463796
Recruiting
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of... Read More
Gender:
All
Ages:
All
Trial Updated:
07/26/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Register for Updates
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
NCT05028829
Recruiting
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/25/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Liver Fibroses, Cirrhosis
Register for Updates
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
NCT05201404
Recruiting
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/15/2023
Locations: Site 881, Dallas, Texas +31 locations
Conditions: Hepatocellular Carcinoma, Cirrhosis
Register for Updates